Teva Leapfrogs One ANDA Sponsor But Faces Decade Wait On US Firdapse Opportunity
Patent-Litigation Settlement Provides For February 2035 Entry; Two Actions Ongoing
Catalyst saw its share price jump by around 14% after striking what the market termed a favorable patent-litigation settlement agreement with ANDA sponsor Teva over its rare disease drug Firdapse.
